2 results
Approved WMOCompleted
Primary objective:To evaluate the objective response rate (ORR) of AZD1775 in combination with gemcitabine, carboplatin, paclitaxel,or PLD in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerSecondary…
Approved WMORecruiting
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues